# KPs Supplement for Inflammation, Oxidative Stress and Lipid Abnormalities in CKD Patients.

> **NCT07260292** · NA · COMPLETED · sponsor: **National Chung Hsing University** · enrollment: 165 (actual)

## Conditions studied

- Chronic Kidney Disease Stage 3
- Chronic Kidney Disease Stage 4
- Proteinuria

## Interventions

- **DIETARY_SUPPLEMENT:** KEFPEP®
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT07260292
- **Lead sponsor:** National Chung Hsing University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-08-01
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07260292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07260292, "KPs Supplement for Inflammation, Oxidative Stress and Lipid Abnormalities in CKD Patients.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07260292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*